Magnitude of dolutegravir associated hyperglycemia and its determinants among people living with HIV in Kolfe Keranyo Wereda 09 health center in Addis Ababa, Ethiopia

Abstract

Background: Since 2019, Dolutegravir has been introduced as a first line therapy and many newly diagnosed HIV patients and patients on other Antiretrovirals are being started on this medication. Dolutegravir based Antiretroviral Therapy (ART) regimen has provided a potent treatment option for people living with HIV/AIDS. However, clinical settings showed growing evidence that dolutegravir could result in significant hyperglycemia. Knowledge of dolutegravir associated hyperglycemia is crucial for early interventions to reduce morbidity and mortality related to hyperglycemia among HIV patients on dolutegravir containing ART drugs. Objective: The objective of this study is to assess the magnitude of hyperglycemia and its determinants among People living with HIV taking dolutegravir based ART regimen. Methods: Facility based cross-sectional study design was used. The calculated sample size was 560. Study participants who will fulfill eligibility criteria were selected. Patients on dolutegravir based regimen for at least 6 months visiting the ART clinic everyday were enrolled until the required sample size reached. Data collection checklist was prepared and trained data collectors collected the data both from patient interview and patient charts by the electronic HIV registration. Data was computed using Epi info version 7.2 and analyzed by SPSS version 20. Fasting blood sugar (FBS) or Random blood sugar (RBS) was done using a point of care glucometer for the study purpose. Descriptive analysis was used to calculate frequency and percentage of the main findings. Logistic regression analysis was done to see association of dependent and independent variables. Result: Of the total 560 participants, more than half (68.6%) of the population studied were females and mean age of participants was 44.09(±9.21) years. Majority of the population (55.7%) were in the age (41-65) years. Hyperglycemia was observed in 189 (33.8%) patients. On multivariate analysis: age 41-65 years (AOR=1.63(1.08-2.46); 95% CI), age >65 years (AOR=4.98(1.33-18.55); 95% CI) and female gender (AOR=1.65(1.06-2.57); 95% CI) were significantly associated with development of hyperglycemia. Conclusion and recommendation: The magnitude of hyperglycemia among patients taking dolutegravir-based antiretroviral regimen was found to be high and it's crucial to ...

Thesis available at Addis Continental Institute of Public Health Library